Human CD20 / MS4A1 Full Length Protein, His Tag (Detergent) (SPR verified)
分子别名（Synonym）
MS4A1, CD20, MS4A-1
表达区间及表达系统（Source）
Human CD20 Full Length Protein, His Tag (CD0-H52H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
Predicted N-terminus: Met 1
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.2 kDa. The protein migrates as 40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
纯度（Purity）
>85% as determined by SDS-PAGE.
制剂（Formulation）
This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumstances should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible with your application, remove glycerol just before the immediate experiment, and NEVER store glycerol-free protein solution.
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 3 months under sterile conditions.
背景介绍
B淋巴细胞抗原CD20（亦称B淋巴细胞表面抗原B1、白细胞表面抗原Leu-16、四次跨膜结构域亚家族A成员1、MS4A1）是一种活化糖基化磷蛋白。该抗原自前B细胞阶段（CD45R+，CD117+）起始表达于所有B细胞表面，其浓度随细胞成熟度逐步递增。除发育首尾阶段外，CD20存在于B细胞发育全程：从晚期前B细胞延伸至记忆B细胞均有表达，但在早期前B细胞、浆母细胞及浆细胞中缺失。该抗原表达于B细胞淋巴瘤、毛细胞白血病、B细胞慢性淋巴细胞白血病及黑色素瘤干细胞表面。其功能虽无已知天然配体，但能介导最佳B细胞免疫应答，特别是针对非T细胞依赖性抗原。学界推测其可能作为钙离子通道存在于细胞膜上。CD20/MS4A1是单克隆抗体利妥昔单抗、替伊莫单抗以及托西莫单抗的作用靶点，这些抗体药物治疗所有类型B细胞淋巴瘤及白血病均具有活性。CD20/MS4A1缺陷是导致普通可变型免疫缺陷病5型（CVID5）的病因，该病又称CD20缺陷性抗体缺乏症，属于以抗体缺乏、低丙种球蛋白血症、反复细菌感染及抗原抗体应答缺失为特征的原发性免疫缺陷病。
关键字： CD20;CD20蛋白;CD20重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。